Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients

NCT ID: NCT00359866

Last Updated: 2016-06-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-02-28
• Study Completion Date: 2016-01-31

Brief Summary

Indications for post-hysterectomy radiation therapy (RT) have been well established by clinical data. Adjuvant RT has demonstrated local control and survival benefit. In patients with nodal disease, adjuvant chemotherapy concurrent with radiation has further improved the clinical outcome. The acute hematological and gastrointestinal toxicity of concurrent chemo-radiotherapy can be quite high, sometimes preventing patients from completed their full treatment course, potentially compromising the therapeutic benefit of treatment. Intensity modulated radiation therapy (IMRT) is an advanced method of delivering external beam radiation that may minimize the volume of normal tissue irradiated to high dose and thus decrease the risk of normal tissue toxicity. Helical tomotherapy is a novel treatment device with sophisticated imaging and treatment delivery features that are optimally suited for IMRT. There are retrospective clinical data supporting the use of non-tomotherapy delivered IMRT to treat patients with gynecologic cancers. The proposed study will prospectively test whether helical tomotherapy is a feasible method for delivering IMRT in post-hysterectomy cervical cancer patients receiving adjuvant RT. Here, the question of feasibility is simply one of verifying that target volumes are reliably covered by 'sculpted' IMRT high-dose regions. Although this is not a treatment effectiveness study, we will also follow the clinical outcome of these patients, including toxicity, local control and survival, in anticipation that this information will be valuable if the treatment modality is judged feasible and will be used for further treatments of this patient population.

Detailed Description

Patients with cervical cancer receiving post-operative radiotherapy (RT) for high risk features found on pathologic review will be treated with pelvic intensity modulated radiation therapy (IMRT). Helical tomotherapy will be used to plan and deliver the radiation treatment. Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions. External beam radiation will be delivered in 180 cGy daily fractions to a total dose of 5040 cGy. Patients will receive once a day treatment five days a week, for approximately 6 weeks. Concurrent chemotherapy and/or intracavitary brachytherapy may be included in the treatment plan at the discretion of the treating physician, consistent with routine clinical practice.

Conditions

Uterine Cervical Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pelvic IMRT with Tomotherapy

Helical tomotherapy will be used to plan and deliver the radiation treatment.

Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.

External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.

Receive treatment once a day for five days a week for approximately 6 weeks.

Treating physician will make determination if patient is to receive intracavitary brachytherapy.

Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated).

Group Type: EXPERIMENTAL

IMRT with tomotherapy

Intervention Type: RADIATION

Interventions

IMRT with tomotherapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Age >= 18
• Karnofsky Performance Status of >= 60
• FIGO Stage I -IIB
• Pathologic confirmation of cervical cancer
• Status post hysterectomy
• Patients with local or regional metastases are eligible for this protocol, but not those with distant metastases

Exclusion Criteria

• Age < 18
• Karnofsky Performance Status < 60
• Radiographic or pathologic evidence of distant metastatic disease
• Prior pelvic radiation therapy, other than trans-vaginal ring brachytherapy irradiation for acute hemostasis

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Perry W Grigsby, M.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University Medical School

Locations

Washington University School of Medicine

St Louis, Missouri, United States

Countries

United States

Related Links

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

05-0977 / 201104019

Identifier Type: -

Identifier Source: org_study_id